These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

861 related articles for article (PubMed ID: 31811434)

  • 1. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
    Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
    Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
    Parkhi M; Chatterjee D; Bal A; Vias P; Yadav BS; Prakash G; Gupta SK; Radotra BD
    APMIS; 2022 Feb; 130(2):82-94. PubMed ID: 34862664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
    Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
    Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
    Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
    Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large cell lymphomas.
    Tabanelli V; Corsini C; Fiori S; Agostinelli C; Calleri A; Orecchioni S; Melle F; Motta G; Rotili A; Di Napoli A; Pileri SA
    Hum Pathol; 2019 Aug; 90():60-69. PubMed ID: 31125630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune parameters associated with survival in metaplastic breast cancer.
    Chao X; Liu L; Sun P; Yang X; Li M; Luo R; Huang Y; He J; Yun J
    Breast Cancer Res; 2020 Aug; 22(1):92. PubMed ID: 32811533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
    Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
    BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).
    Berghoff AS; Ricken G; Widhalm G; Rajky O; Hainfellner JA; Birner P; Raderer M; Preusser M
    Clin Neuropathol; 2014; 33(1):42-9. PubMed ID: 24359606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
    Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
    Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of programmed cell death ligand-1 by immune cells in the microenvironment is a favorable prognostic factor for primary diffuse large B-cell lymphoma of the central nervous system.
    Tsuyuki Y; Ishikawa E; Kohno K; Shimada K; Ohka F; Suzuki Y; Mabuchi S; Satou A; Takahara T; Kato S; Miyagi S; Ozawa H; Kawano T; Takagi Y; Hiraga J; Wakabayashi T; Nakamura S
    Neuropathology; 2021 Apr; 41(2):99-108. PubMed ID: 33269495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD1 distribution pattern, regardless of the cell origin, is an independent microenvironmental prognostic factor for progression-free survival in follicular lymphoma.
    Szumera-Ciećkiewicz A; Poleszczuk J; Kuczkiewicz-Siemion O; Paszkiewicz-Kozik E; Rymkiewicz G; Sokół K; Borysiuk A; Kotarska M; Kawecka M; Owczarek D; Pytlak B; Walewski J; Prochorec-Sobieszek M
    Pathol Res Pract; 2020 Oct; 216(10):153096. PubMed ID: 32853965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed cell death-ligand 1 (PD-L1)
    Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Mihashi Y; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
    Clin Exp Med; 2022 Aug; 22(3):411-419. PubMed ID: 34515880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.
    Menter T; Bodmer-Haecki A; Dirnhofer S; Tzankov A
    Hum Pathol; 2016 Aug; 54():17-24. PubMed ID: 27045512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
    Xie M; Huang X; Ye X; Qian W
    Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
    Rosado FG; Coberly J; Gupta A; John G; Naina H; Koduru P; Chen W
    Ann Clin Lab Sci; 2021 Mar; 51(2):174-181. PubMed ID: 33941556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation study of PD-L1, CD4, CD8, and PD-1 in primary diffuse large B-cell lymphoma of the central nervous system.
    Liu B; Yan S; Li S; Zhang Q; Yang M; Yang L; Ma J; Li X
    Pathol Res Pract; 2022 Nov; 239():154008. PubMed ID: 36183436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets.
    Mitteldorf C; Berisha A; Pfaltz MC; Broekaert SMC; Schön MP; Kerl K; Kempf W
    Am J Surg Pathol; 2017 Jul; 41(7):998-1004. PubMed ID: 28504999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
    Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
    Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.